Boardroom Alpha
Boardroom Alpha
HSTM · Current Report (Form 8-K) · Filed May 8, 2026

Healthstream Inc — Current Report (Form 8-K)

Form
8-K
Filed
May 8, 2026
Period
May 4, 2026
Ticker
HSTM
Accession
0001437749-26-015956
Boardroom Alpha · Filing insights

HealthStream promotes Michael Collier to COO/EVP; grants 18,781 stock options at $23.96; CEO Frist also granted 18,781 options.

About Healthstream Inc
Market cap
$737M
1Y TSR
−14.2%
3Y TSR
−0.2%
Board grade
B+
Sector
Healthcare
CEO
Robert A Frist Jr
Last annual meeting: May 28, 2026 · View full Healthstream Inc profile →
hstm20260506_8k.htm
 


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

 
 
FORM 8-K
 
 

 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 8, 2026 (May 4, 2026)
 

 
HealthStream, Inc.
(Exact name of Registrant as Specified in Its Charter)
 
 

 
Tennessee
000-27701
62-1443555
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
     
500 11th Avenue North, Suite 850,
Nashville, Tennessee
 
37203
(Address of Principal Executive Offices)
 
(Zip Code)
 
Registrants Telephone Number, Including Area Code: 615-301-3100
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
 

 
Securities registered pursuant to Section 12(b) of the Act:
 
 
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock (Par Value $0.00)
HSTM
Nasdaq Global Select Market
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
 
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
 
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
 
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
 
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 
 
 

 
 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
 
Promotion of Michael M. Collier 
 
As disclosed by HealthStream, Inc. (the “Company”) in a press release issued on May 4, 2026, announcing the Company’s results of operations for the three months ended March 31, 2026, Michael M. Collier has been promoted to the Company’s Chief Operating Officer and Executive Vice President from his prior role as the Company’s EVP, Corporate Strategy, Development & Operations. In this role, Mr. Collier will lead enterprise operations across HealthStream, including customer experience functions, corporate development and mergers and acquisitions, implementations, legal, human resources, partnerships, business enablement, and other critical areas. In addition, Mr. Collier will serve as the executive sponsor for the Company’s AI transformation, driving AI readiness across operational teams and advancing the use of AI to support the workforce and internal business processes.  
  
Pursuant to the terms of a letter agreement entered into between the Company and Mr. Collier in connection with such promotion (the “Collier Letter Agreement”), the Company’s Compensation Committee (the “Committee”) approved the grant to Mr. Collier of stock options to acquire 18,781 shares of the Company’s common stock pursuant to the Company’s shareholder-approved 2022 Omnibus Incentive Plan (the “2022 Plan”) at an exercise price of $23.96 per share, which equals the closing market price on the grant date of May 8, 2026. In addition, these options will vest on a time-based basis in the following increments: 15% on the first anniversary of the grant date; 20% on the second anniversary of the grant date; 20% on the third anniversary of the grant date; 20% on the fourth anniversary of the grant date; and 25% on the fifth anniversary of the grant date, subject to Mr. Collier’s continued service with the Company. In connection with such promotion, the Collier Letter Agreement also provides, among other things, for an increase in the annual base salary of Mr. Collier, Mr. Collier’s eligibility to participate in the Company’s annual cash bonus plan at the executive vice president level, and Mr. Collier’s eligibility to receive an annual award of time-based vesting RSUs. 
  
There is no arrangement or understanding between Mr. Collier and any other person pursuant to which Mr. Collier was selected for such role. Mr. Collier has no family relationships with any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer of the Company. Mr. Collier is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. A description of Mr. Collier’s business background and experience is incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed on February 26, 2026. 
 
Equity Grant to Robert A. Frist, Jr. 
 
The Committee also approved a grant to the Company’s Chief Executive Officer, Robert A. Frist, Jr., of stock options to acquire 18,781 shares of the Company’s common stock pursuant to the 2022 Plan at an exercise price of $23.96 per share, which equals the closing market price of the Company’s common stock on the grant date of May 8, 2026. In addition, these options will vest on a time-based basis in the following increments: 15% on the first anniversary of the grant date; 20% on the second anniversary of the grant date; 20% on the third anniversary of the grant date; 20% on the fourth anniversary of the grant date; and 25% on the fifth anniversary of the grant date, subject to Mr. Frist’s continued service with the Company. 
 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
   
HealthStream, Inc.
       
Date: May 8, 2026
 
By:
/s/ Scott A. Roberts
     
Scott A. Roberts
     
Chief Financial Officer
 
 
From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Healthstream Inc (HSTM)

Reference

Frequently asked questions

When did Healthstream Inc file this 8-K?
Healthstream Inc (HSTM) filed this Current Report (Form 8-K) with the SEC on May 8, 2026. The accession number assigned by EDGAR is 0001437749-26-015956.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
HealthStream promotes Michael Collier to COO/EVP; grants 18,781 stock options at $23.96; CEO Frist also granted 18,781 options. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Healthstream Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Healthstream Inc has filed under CIK 1095565, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer